KURA
Kura Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.25
+0.76%Margins
Gross margin
94.7%
EBITDA margin
-378.6%
EBIT margin
-411.9%
Net margin
-384.3%
FCF margin
-152.1%
-612.8%
Return on equity
-50.5%
Return on assets
-436.4%
Return on invested capital
0.12x
Asset turnover
-$111.8M
Cash from operations
$5.83
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026